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ABSTRACTS 
IC EFFECT OF 
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Secondary sympathetic activation with wasodilating 
agents can mask these drugs' intrinsic negative 
inotropic effect. Accordingly, we developed a new method 
to assess LW contractility independent of load and 
reflex sympathetic changes. 14 non-ischemic hypertensive 
pts (mean BP=124114 Hg) were studied using echo-Doppler 
while on placebo and 1 wk after therapy with nifedipine 
(Nif). LW end systolic stress (ESS) - rate corrected 
velocity of shortening (Wcfc) 
over a range of loads induced b 
was assessed using Wcfc at a co n LW afterload. At 
each study, data were acquired ore and during IV 
esmolol (Esm) to determine the presence of significant 
reflex cardiac sympathetic responses. The adequacy of 6.. 
sessed with isuprel. 
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In 12/14 pts, nlfedipine au 
contractility. Ablation of 
with esmolol unmasked nifedipine's negative fnotropic 
effect in 9/14 pts. Thus, this noninvasive technique can 
be used to isolate intrinisic contractility changes in 
drugs with combined wasodilator and inotropic action. 
IS ATROPHY A FORM OF CARDIAC ADAPTATION? A STUDY 
PATIENTS WfIH CHRONIC SPINAL CORD NURY 
OF 
Susan B Eysmann, Jeanne If Wei. l¶RY 
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LV mass index (LVMI) was significanlly lower in SC1 than in N (78+-10 
vs 9%7 gh2, j?=.CKll). LV e&d&t& and end-systolic volumes and h were the 
same in both groups, although CO (4.3+-l vs 5.1~..7 Umin), saoke volume (69+- 
13 vs 79+-12 ml), and LA size (3.2+-5 vs 3.7+-.4 cm) were reduced in SC1 
@<.OS). In spile of reductions in LVMI, LV chamber architecture. as described by 
rclaUve wall thiclore-ss .Wi3S 
normal. Resting supin er in 
SC1 (103+-17 vs 127+ end- 
systolic circumferemial wall stress was reduced (143=+44 vs 177+-34 kdkm2, 
pc.03). Ejection fraction and LV fdling pattern were similar in bolh groups. SC1 
had shoner aortic ejection times (.29+-M vs .38+.Q9 sec. p.03) and longer 
accekation tinrz to ejecti .07 vs 28t.06, p=.Ol) suggestive of 
mild systolic dysfunction. w of reducedLVM1 inSCIina 
stepwise regn&on model viky. lower systolic BP and advanced 
findings suggest similar 
INFLUENCE OF INOTROPIC AGENTS ON LEFT VENTRICliLAR 
CONTRACTILITY AND MYOCARDIAL ENERGETICS IN PATIENTS 
WlTH DILATED CARDIOMYOPATHY 
Hitoshl lshlhara, Mitsuhiro Yokota, Ryozo K&oh, Tatsuyukl 
Matsunami 
Nagoya University, Nagoya, Japan 
Left. ventricular contractile state and energy conversion 
efficiency were investigated in 11 patients with dilated 
cardiomyopathy, using left ventricular pressure-volume 
relation before and after administration of dobutamlne(DOB) 
and oral phosphodiesterase inhibitor(MS-857). Pressure- 
volume area(PVA), external work(EW), end-systolic 
elastance(Ees), and effective arterial elast.ance(Ea) were 
measured using continuous pressure-volume diagram 
obtained by a conductance catheter. Myocardlal oxygen 
consumpiion iMV&) was measured using coronary sinus flow 
and oxygen difference from a coronary sinus catheter. 
After administration of MS-857 and DOB, slgnlflcant 
increase in Ees(l.OO to 1.35 mmHg/ml after MS-857, and 1.12 
Lo 1.54 after DOB), decrease in Ea(2.75 to 2.35 mmHg/ml after 
MS-857, and 2.45 to 2.15 after DOB), and decrease In Ea/Ees 
(3.15 to 2.07 after MS-857, and 2.84 to 1.54 after DOB) toward 
a so called optimal ventriculoarterial coupling were observed. 
As a result, EW/PVA efficiency increased from 33 to 40% after 
MS-857 and from 34 to 112% after DOB. 
Both energy conversion efficiency PVA/MVO, and Ek/MVO;. 
had a inverse relation to Ees(r=-0.81 and r=-0.78, p<O.O5), 
while EW/PVA increased with Ees(r=Q.66,p<0.05). In 
conclusion, inotropic agents increase contractility and 
external work efficiency, but have a possibility of oxygen 
wasting effect in patients with dilated cardiomyopathy. 
Alan S. Wolllister, Ted 
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order to measure the ynamic and renal 
cts of atria1 natriure actor (ANF), we 
infused ANF at 0.01, 0.03 and 0.1 ug/kg/min for 
45 min at each dose in 5 class IV heart failure 
(CHF) and 5 normal (Nl) subjects during 
continuous hemodynamic monitoring. Plasma ANF 
levels increased similarly in both groups (Nl: 
2425 to 1105+147, CHF: 117222 to 1470~158 pg/ml 
PcO.001 for both) and were associated with 
significant fa 
CHF: -6.5k1.6 
-5.2 +0.3, CHF 
capillary wedge pressures (PCWP) (Nl: -5.QO.6, 
CHF: -12.722.1) (all p<O.OOl) at the highest 
dose. The final filling pressures in CHF (RA: 
5.7+ 2.8, PCWP 11.123.5 mmHg) were similar to 
the-initial pressures in Nl (RA: 6.022.1, PCWP 
9.823.6 mmHg, P=NS for both). Urine flow rate 
rose significantly in both groups (Nl: 6.6i1.2 
to 25.796.3 ml/min, CHF: 2.2+0.6 to 7.Q3.4, 
~~0.05 for both). Urine sodTurn loss rose in a 
similar significant fashion (nl: 211 
1367+179 and CHF: 17&4 to 232+73 uEg/ 
for both). 
We conclude that the hemo 
and natriuretic effects of F are ravorable 
and can normalize the baseline abnormalities 
that exist in end-stage heart failure. 
